416 filings
Page 2 of 21
8-K
ei96d 6cpcrsq
18 Oct 23
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
4:30pm
8-K
t1ld89
13 Oct 23
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
4:47pm
8-K
vaoaey
14 Sep 23
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
4:10pm
8-K
dbely859pyi
27 Jun 23
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025
4:06pm
8-K
1u2cq4e20u33flp 54ck
20 Jun 23
Regulation FD Disclosure
6:55am
8-K
v6gn6iag
2 Jun 23
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:30pm
8-K
3myn4
26 May 23
Submission of Matters to a Vote of Security Holders
12:00am
8-K
nfmbw351
11 May 23
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
4:15pm
DEFA14A
vn5ycdx
12 Apr 23
Additional proxy soliciting materials
4:19pm
8-K
7xnhl6s4u1
10 Feb 23
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
4:10pm
8-K
a3ync789
13 Jan 23
Departure of Directors or Certain Officers
4:16pm
8-K
uh0vmb1w48q
15 Dec 22
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
4:54pm
EFFECT
sxljc
10 Nov 22
Notice of effectiveness
12:15am
8-K
vewffajsi7t5 tvlzk6
9 Nov 22
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
4:12pm
S-8
tpwgi1 yaj
7 Nov 22
Registration of securities for employees
4:24pm